Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819562 | 0.83 | DDB1 (0.58) | DDB1CRBNMAPTGPR119 | |
| SCHEMBL30831013 | 0.79 | DDB1 (0.54) | DDB1CRBNGPR119 | |
| SCHEMBL20437001 | 0.79 | DDB1 (0.57) | DDB1CRBNMAPTGPR119 | |
| SCHEMBL23302014 | 0.77 | CRBN (0.56) | DDB1CRBN | |
| SCHEMBL30830951 | 0.77 | CRBN (0.61) | DDB1CRBNTP53GPR119 | |
| SCHEMBL20812034 | 0.76 | CRBN (0.65) | DDB1CRBNTHRBMAPT | |
| SCHEMBL26665900 | 0.76 | DRD2 (0.48) | TP53THRBMAPTGPR119DRD2 | |
| SCHEMBL30304647 | 0.76 | DDB1 (0.66) | DDB1CRBNMAPT | |
| SCHEMBL21997585 | 0.75 | CRBN (0.58) | DDB1CRBNGPR119 | |
| SCHEMBL30658467 | 0.75 | IKZF1 (0.58) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |